A Study to Evaluate the Safety and Tolerability of ABBV-951 in Subjects With Parkinson's Disease (PD) [M15-741]
Phase 3
Completed
- Conditions
- Parkinson's Disease
- Registration Number
- JPRN-jRCT2080224809
- Lead Sponsor
- AbbVie G.K
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- completed
- Sex
- All
- Target Recruitment
- 13
Inclusion Criteria
Subjects with diagnosis of idiopathic Parkinson's Disease (PD) that is levodopa -responsive
- Subjects must be judged by the investigator to be inadequately controlled by current therapy, have recognizable/identifiable Off and On states (motor fluctuations), and have a minimum of 2.5 hours of Off time per day
Exclusion Criteria
- Subject is cognitively impaired and is not able to safely and effectively manage the drug delivery system and the diaries and is not able to adhere to the study.
- Subject is considered by the investigator to be an unsuitable candidate to receive ABBV-951 for any reason.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method